Loading...
Back to narrative

AnalystConsensusTarget updated the narrative for ASTERDM

Analysts Raise Aster DM Healthcare Price Target as Profit Margins Improve and Valuation Increases

ASTERDM logo
ASTERDM
AnalystConsensusTarget
Not Invested
Published 09 Feb 2025

Update shared on 23 Oct 2025

Fair value Increased 4.36%
PreviousNext
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
29.2%
7D
-2.3%

Narrative Update on Aster DM Healthcare

Analysts have revised their price target for Aster DM Healthcare upward from ₹675 to ₹704.44, reflecting improved profit margin expectations, even as revenue growth projections have been slightly moderated.

What's in the News

  • The company approved a final dividend of INR 1 per equity share for the financial year ended March 31, 2025. The Annual General Meeting will be held on September 4, 2025.
  • Aster DM Healthcare established a wholly owned subsidiary, Aster DM Super-Specialty Hospital (Yeswanthpur) Private Limited, in Bengaluru, Karnataka. The subsidiary was incorporated on July 28, 2025 to set up and operate a super-specialty hospital.
  • The Board of Directors held a meeting on July 30, 2025 to consider and approve the unaudited financial results for the quarter ended June 30, 2025. The Board Meeting took place on July 30, 2025.

Valuation Changes

  • Consensus Analyst Price Target has increased from ₹675 to ₹704.44, indicating a positive adjustment in valuation.
  • Discount Rate remains unchanged at 12.73%.
  • Revenue Growth expectations have decreased from 44.76% to 41.56%.
  • Net Profit Margin is projected to rise from 9.55% to 10.48%.
  • Future P/E ratio has edged up from 43.72x to 44.47x.

Have other thoughts on Aster DM Healthcare?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.